Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications
- PMID: 19954478
- DOI: 10.1111/j.1744-9987.2009.00775.x
Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications
Abstract
Reducing sugars can react non-enzymatically with amino groups of protein to form Amadori products. These early glycation products undergo further complex reactions, such as rearrangement, dehydration, and condensation, to become irreversibly cross-linked, heterogeneous fluorescent derivatives, termed advanced glycation end products (AGEs). The formation and accumulation of AGEs have been known to progress at an accelerated rate in patients with diabetes mellitus, thus being involved in the development and progression of diabetic micro- and macroangiopathy. Indeed, there is accumulating evidence that an interaction between an AGE and its receptor (RAGE) generates oxidative stress and subsequently evokes vascular inflammation and thrombosis, thereby playing a central role in diabetic vascular complications. In this paper, we review the pathophysiological role of AGE-RAGE-oxidative stress system and its therapeutic interventions in diabetic micro- and macroangiopathy.
Similar articles
-
Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.Exp Gerontol. 2011 Apr;46(4):217-24. doi: 10.1016/j.exger.2010.11.007. Epub 2010 Nov 25. Exp Gerontol. 2011. PMID: 21111800 Review.
-
A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.Med Hypotheses. 2007;69(2):338-40. doi: 10.1016/j.mehy.2006.11.054. Epub 2007 Feb 27. Med Hypotheses. 2007. PMID: 17329034
-
Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.Med Hypotheses. 2005;65(5):953-5. doi: 10.1016/j.mehy.2005.05.006. Med Hypotheses. 2005. PMID: 15996828
-
Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.Med Hypotheses. 2005;65(2):392-4. doi: 10.1016/j.mehy.2004.12.016. Med Hypotheses. 2005. PMID: 15922119
-
Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.Curr Drug Targets. 2007 Oct;8(10):1138-43. doi: 10.2174/138945007782151298. Curr Drug Targets. 2007. PMID: 17979674 Review.
Cited by
-
Inflammation Meets Metabolism: Roles for the Receptor for Advanced Glycation End Products Axis in Cardiovascular Disease.Immunometabolism. 2021;3(3):e210024. doi: 10.20900/immunometab20210024. Epub 2021 Jun 2. Immunometabolism. 2021. PMID: 34178389 Free PMC article.
-
Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment.Open Cardiovasc Med J. 2010 Nov 26;4:240-56. doi: 10.2174/1874192401004010240. Open Cardiovasc Med J. 2010. PMID: 21270942 Free PMC article.
-
Effects of levocarnitine on brachial-ankle pulse wave velocity in hemodialysis patients: a randomized controlled trial.Nutrients. 2014 Dec 22;6(12):5992-6004. doi: 10.3390/nu6125992. Nutrients. 2014. PMID: 25533009 Free PMC article. Clinical Trial.
-
Novel drugs and their targets in the potential treatment of diabetic retinopathy.Med Sci Monit. 2013 Apr 26;19:300-8. doi: 10.12659/MSM.883895. Med Sci Monit. 2013. PMID: 23619778 Free PMC article. Review.
-
Inhibitory effects and actions of pentacyclic triterpenes upon glycation.Biomedicine (Taipei). 2015 Sep;5(3):13. doi: 10.7603/s40681-015-0013-x. Epub 2015 Aug 11. Biomedicine (Taipei). 2015. PMID: 26260291 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
